Prosecution Insights
Last updated: April 19, 2026

Grund Intellectual Property Group

6 pending office actions • 5 clients

Portfolio Summary

6
Total Pending OAs
2
Final Rejections
4
Non-Final OAs

Client Portfolio (5 clients)

Client (Assignee)Pending OAs
Livingmed Biotech S.r.l. 2
Highlight Therapeutics, S.L. 1
Elisabeth Zeisberg 1
Merz Therapeutics GmbH 1
UNIVERSITÄT BIELEFELD 1

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
18546427 GENETICALLY MODIFIED CLOSTRIDIUM STRAINS EXPRESSING RECOMBINANT ANTIGENS AND USES THEREOF Livingmed Biotech S.r.l. FOLEY, SHANON A 1671 Non-Final OA Aug 14, 2023
18349989 NOVEL COMPOSITIONS BASED ON POLYINOSINIC-POLYCYTIDYLIC ACID Highlight Therapeutics, S.L. ZARA, JANE J 1637 Non-Final OA Jul 11, 2023
17917958 ALL-IN-ONE AAV VECTORS FOR TREATING CORONAVIRUS-INDUCED DISEASES Elisabeth Zeisberg HUDSON, AMY ROSE 1636 Final Rejection Oct 10, 2022
17787381 GENETICALLY MODIFIED CLOSTRIDIUM STRAINS AND USES THEREOF Livingmed Biotech S.r.l. SINGH, SATYENDRA K 1657 Final Rejection Jun 20, 2022
17767725 METHOD FOR PREVENTING HUMAN GLANDS FROM RADIATION DAMAGE Merz Therapeutics GmbH DAVIS, RUTH A 1699 Non-Final OA Apr 08, 2022
17642054 METHOD FOR THE PRODUCTION OF RAAV AND METHOD FOR THE IN VITRO GENERATION OF GENETICALLY ENGINEERED, LINEAR, SINGLE-STRANDED NUCLEIC ACID FRAGMENTS CONTAINING ITR SEQUENCES FLANKING A GENE OF INTEREST UNIVERSITÄT BIELEFELD YAMASAKI, ROBERT J 1657 Non-Final OA Mar 10, 2022

Managing Grund Intellectual Property Group's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month